Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Replimune Group, Inc. due to allegations of violations of federal securities laws related to misleading statements about the IGNYTE trial and its FDA approval process [1][3]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Replimune between November 22, 2024, and July 21, 2025, to contact them regarding their legal rights [1]. - A federal securities class action has been filed against Replimune, with a deadline of September 22, 2025, for investors to seek the role of lead plaintiff [1][5]. Group 2: Allegations Against Replimune - The complaint alleges that Replimune and its executives overstated the prospects of the IGNYTE trial, which the FDA deemed inadequate and not well-controlled [3]. - The lawsuit claims that the misleading statements about Replimune's business and operations led to investor damages when the true details were revealed [3]. Group 3: Market Reaction - Following the announcement of a Complete Response Letter from the FDA regarding the Biologics License Application for RP1, Replimune's stock fell over 73% during intraday trading on July 22, 2025 [4].

Core Points - Rosen Law Firm is reminding purchasers of Replimune Group, Inc. securities about a class action lawsuit with a lead plaintiff deadline of September 22, 2025 [1][3] - Investors who purchased Replimune securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] Case Details - The lawsuit alleges that defendants made materially false and misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate and not well-controlled [5] - As a result of these misleading statements, investors suffered damages when the true details were revealed [5] Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6] - It is noted that no class has been certified yet, and investors may choose to remain absent or select their own counsel [7] Rosen Law Firm's Credentials - The firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4]

Core Viewpoint - Replimune Group, Inc. is facing a class action lawsuit due to alleged misleading statements regarding the prospects of its IGNYTE trial, which led to a significant stock price drop after the FDA's response [4][5]. Group 1: Company Overview - Replimune is a clinical-stage biotechnology company focused on developing and commercializing oncolytic immunotherapies for cancer treatment [3]. Group 2: Legal Allegations - The class action lawsuit claims that Replimune's management made false and misleading statements about the IGNYTE trial, which they knew or should have known were overstated [4]. - The lawsuit highlights that the FDA deemed the IGNYTE trial inadequate and not well-controlled, impacting the company's credibility [4]. Group 3: Financial Impact - Following the FDA's issuance of a Complete Response Letter regarding the Biologics License Application for RP1, Replimune's stock price plummeted by over 77% [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Replimune Group, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Replimune securities class action is from November 22, 2024, to July 21, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must file a motion with the Court by September 22, 2025, to represent other class members in the litigation [3]. Group 2: Case Allegations - The lawsuit alleges that defendants made materially false and misleading statements regarding the IGNYTE trial's prospects, which were known to be inadequate by the defendants [5]. - The U.S. Food and Drug Administration (FDA) deemed the IGNYTE trial inadequate and not well-controlled, impacting the credibility of Replimune's business statements [5]. - Investors suffered damages when the true details about the trial and the company's operations were revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time [4]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in recovering funds for clients [4].

Core Viewpoint - A securities class action lawsuit has been filed against Replimune Group, Inc. alleging that the company misled investors regarding the success of its cancer drug RP1, resulting in a 77% stock price crash after the FDA rejected its application [1][2]. Group 1: Lawsuit Details - The lawsuit, Jboor v. Replimune Group, Inc., represents investors who purchased Replimune securities between November 22, 2024, and July 21, 2025 [1][2]. - The FDA issued a "Complete Response Letter" on July 22, 2025, rejecting the Biologics License Application for RP1, which led to a significant sell-off and a 77% decline in stock price [2][4]. Group 2: Allegations of Misleading Information - The lawsuit claims that Replimune presented an overly optimistic view of the drug's prospects, failing to disclose regulatory concerns that contributed to the stock's collapse [3][4]. - The FDA's rejection letter indicated that the IGNYTE trial was not "well-designed" and lacked substantial evidence of effectiveness due to issues such as patient heterogeneity and flawed design [6][7]. Group 3: Investigation and Implications - Hagens Berman is investigating whether Replimune misled investors about the IGNYTE trial, which was central to the drug's application [5][6]. - The investigation focuses on whether management was aware of the trial's fundamental weaknesses and did not disclose them to investors [6][7].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Replimune Group, Inc. regarding a class action lawsuit due to alleged misleading statements related to the IGNYTE trial [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from November 22, 2024, to July 21, 2025 [1]. - The complaint claims that defendants overstated the IGNYTE trial's prospects, leading to the FDA deeming the trial inadequate [1]. - It is alleged that the defendants' statements about Replimune's business and operations were materially false and misleading [1]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by September 22, 2025, to potentially be appointed as lead plaintiff [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2]. - Participation in the case incurs no cost or obligation for shareholders [2]. Group 3: About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - Replimune Group Inc. faces significant backlash from investors following a regulatory setback that has led to a dramatic decline in its stock price, primarily due to allegations of misrepresentation regarding its cancer therapy RP1 and its clinical trial data [1][4]. Regulatory Setback - On July 22, 2025, Replimune announced that the FDA issued a Complete Response Letter (CRL) for its Biologics License Application for RP1, halting the drug's approval process due to concerns about the adequacy of the clinical data [3][6]. - The stock price plummeted by 77% in a single trading session, resulting in billions in lost market capitalization [4]. Legal Allegations - A class action lawsuit has been filed on behalf of investors who purchased Replimune stock between November 22, 2024, and July 21, 2025, claiming that the company misrepresented the likelihood of regulatory success and failed to disclose material deficiencies in its trial design [2][3]. - The lawsuit highlights that Replimune emphasized RP1's "durable response" data while allegedly concealing critical information regarding the trial's design flaws [5]. FDA Concerns - The FDA's rejection was based on two main issues: the trial's design was not sufficiently rigorous to meet FDA standards, and the patient population was deemed too heterogeneous, complicating the assessment of RP1's efficacy [7][8]. - The agency also raised questions about the ability to isolate the effects of RP1 from other drugs used in combination during the trial [8]. Investor Investigation - Hagens Berman Sobol Shapiro LLP is investigating whether Replimune misled investors about regulatory risks and trial limitations, emphasizing the importance of transparency in clinical trial data [7].

Financial Data and Key Metrics Changes - The meeting reported that at least 70,621,628 shares of common stock were represented, out of a total of 77,807,174 shares outstanding, indicating a quorum for business transactions [6][7]. Business Line Data and Key Metrics Changes - No specific data or metrics related to individual business lines were provided in the meeting. Market Data and Key Metrics Changes - No specific market data or metrics were discussed during the meeting. Company Strategy and Development Direction and Industry Competition - The company proposed the election of several directors and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending 03/31/2026, indicating a focus on governance and compliance [11]. Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting. Other Important Information - The proposal to approve an amendment to the Replimune Group, Inc. 2018 Omnibus Incentive Plan was not passed by the stockholders, which may indicate challenges in aligning executive compensation with shareholder interests [13]. Summary of Q&A Session - No questions or answers were recorded during the meeting.

Core Viewpoint - A securities class action lawsuit has been filed against Replimune Group, Inc. for allegedly making materially false and misleading statements regarding its business and product prospects during the specified class period from November 22, 2024, to July 21, 2025 [1][2]. Group 1: Allegations Against Replimune - The complaint claims that Replimune overstated the trial prospects for its lead product candidate [2]. - It is alleged that the statements made by the defendants about the company's business, operations, and prospects were materially false and misleading, lacking a reasonable basis throughout the class period [2]. Group 2: Lead Plaintiff Process - Investors in Replimune have until September 22, 2025, to seek appointment as a lead plaintiff representative of the class [3]. - The lead plaintiff will act on behalf of all class members and is typically the investor or small group of investors with the largest financial interest [3]. Group 3: Firm Information - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has recovered billions for victims of fraud and corporate misconduct [4]. - The firm encourages Replimune investors who have suffered significant losses to contact them for more information [4].

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of Replimune Group, Inc. (NASDAQ: REPL)?Did you purchase your shares between November 22, 2024, and July 21, 2025, inclusive?Did ...